Kumar S, Harrison S, Cavo M, et al. A phase 3 study of venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. 24th Congress of EHA, abstract LB2601.
Olutasidenib met of zonder azacitidine bij IDH1-gemuteerde AML en MDS
feb 2023 | Leukemie, MDS